FDA 483 - Qilu Pharmaceutical (Hainan) Co. Ltd. - August 22, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Qilu Pharmaceutical (Hainan) Co., Ltd. in Haikou, China, revealed significant deficiencies in their finished drug product manufacturing. Observations included a lack of validated control procedures for manufacturing processes, undersized equipment leading to operational errors, and the use of laboratory instruments that did not meet established specifications, specifically dissolution testers with asymmetrical basket rotation. These issues indicate potential risks to product quality and consistency.
ID · 08dbc3b0-c579-435b-991a-a9343a69dc78